Nuformix PLC Grant of Warrants (4909Y)
06 December 2017 - 6:00PM
UK Regulatory
TIDMNFX
RNS Number : 4909Y
Nuformix PLC
06 December 2017
Nuformix plc
("Nuformix" or "the Company")
Grant of Warrants at 6p per share
Nuformix, the pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs, announces that Warrants over new ordinary shares
have been granted to Beaufort Securities Limited, and have vested
in accordance with the terms agreed with its recent appointment as
the Company's broker:
Warrants over no. Exercise price Lapse date
of shares per share
------------------ --------------- ------------
1,000,000 6 pence 20 November
2020
------------------ --------------- ------------
Follow Nuformix on Vox Markets: follow at
www.voxmarkets.co.uk/company/NFX
and www.nuformix.com
Market Abuse Regulation (MAR) Disclosure. Certain information
contained in this announcement would have been deemed inside
information for the purposes of Article 7 of Regulation (EU) No
596/2014 until the publication of this announcement via a
Regulatory Information Service and accordingly, this inside
information is now considered to be in the public domain.
ENDS
Enquiries:
Nuformix plc
Dan Gooding, Chief Executive +44 (0)1223
Officer 423667
Beaufort Securities Limited
(Joint Broker) +44 (0)20 7382
Jon Belliss 8300
Gable Communications Ltd +44 (0)20 7193
John Bick / Justine James 7463
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix' risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix has created an IP portfolio containing a range of
granted patents covering cocrystal forms of five small molecule
drugs. Nuformix is targeting high-value unmet needs with its lead
programmes in oncology supportive care: NXP001 and fibrosis:
NXP002.
Nuformix was established in Cambridge in 2008 and has invested
into pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities. Nuformix plc shares are
traded on the London Stock Exchange's Official List under the
ticker: NFX.L.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEEAAASESLXFAF
(END) Dow Jones Newswires
December 06, 2017 02:00 ET (07:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2024 to May 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From May 2023 to May 2024